HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TAGRISSO monotherapy in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations and MET overexpression. The combination also showed very encouraging clinical benefit in overall survival (OS).
Curves continued to separate with longer follow-up
–
Magnitude of benefit expanded over time
Subgroup Consistency:Consistent PFS and OS benefits were observed across all pre-specified ITT subgroups, reinforcing the robustness of the combination effect.
Market Impact & Outlook
First-Line Paradigm Shift: Targeting MET overexpression — a known resistance and poor-prognosis factor in EGFR-mutant NSCLC — with upfront savolitinib plus osimertinib challenges the current third-generation EGFR TKI monotherapy standard in biomarker-selected patients.
Biomarker-Defined Opportunity: The dual-population benefit (both IHC 3+ and IHC 2+/3+) supports routine MET IHC testing alongside EGFR mutation screening at diagnosis, potentially reshaping Chinese NSCLC diagnostic pathways.
Franchise Synergy: SANOVO strengthens the commercial pairing of ORPATHYS (HutchMed/AstraZeneca) and TAGRISSO (AstraZeneca), deepening the MET-directed oncology franchise in one of the world’s largest lung cancer markets.
Durable Survival Signal: The widening OS separation and 67.4% three-year survival suggest a long-tail benefit characteristic of effective targeted combinations — a compelling value proposition for payers and guidelines.
Next Steps: Regulatory submission plans were not disclosed in the announcement.
Forward‑Looking Statements This brief contains forward‑looking statements regarding the SANOVO study, the ORPATHYS plus TAGRISSO combination, and potential regulatory submissions or commercialization. Actual results may differ due to risks including final data maturation, regulatory review decisions, reimbursement outcomes, and competitive dynamics in EGFR-mutant NSCLC treatment.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
